2 NIPER's faculty members included in CDSCO's expert panel to evaluate herbal drugs

Image
Press Trust of India Mohali
Last Updated : Aug 13 2018 | 7:50 PM IST

Two faculty members of National Institute of Pharmaceutical Education and Research (NIPER) here have been included in an expert panel set up by the Central Drugs Standard Control Organisation (CDSCO) to evaluate new herbal drugs for their regulatory approval.

Arvind K Bansal, the head of NIPER's Pharmaceutics Department and Saranjit Singh, the head of its Pharmaceutical Analysis Department are among the 12 experts who will evaluate the manufacturing, purification, quality control and toxicological data of the new herbal drugs, also called phyto-pharmaceuticals, said NIPER in a statement.

The expert panel is mandated to advise the Drugs Controller General of India (DCGI) on evaluation of "chemistry-manufacturing control data" including identification, authentication and source of plants used for extraction, purification, formulation and manufacturing of herbal drugs for their approval.

The expert committee would also be engaged in the preparation of guidelines for marketing approval of new phyto-pharmaceuticals of different therapeutic categories, the NIPER's release said.

Other experts include Delhi Pharmaceutical Sciences & Research University's Vice Chancellor Ramesh K Goyal, Indian Institute of Integrative Medicine Director Ram Viswakarma and IIT-BHU's Professor Siva Hemalatha of its Department of Pharmaceutical Engineering.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 13 2018 | 7:50 PM IST

Next Story